中危主动脉瓣狭窄患者经导管与外科主动脉瓣置换术的成本-效用分析
本研究从加拿大第三方支付方角度构建概率马尔可夫模型,比较中危重度主动脉瓣狭窄患者接受经导管主动脉瓣植入与外科主动脉瓣置换的终生成本与质量调整生命年。结果显示经导管策略终生成本高10548加元但增加0.23个质量调整生命年,增量成本-效用比为46083加元/质量调整生命年。作者认为经导管策略可能具有成本-效用,但存在中至高度不确定性。
要点
- 中危主动脉瓣狭窄患者经导管策略终生成本较外科高10548加元,增加0.23个质量调整生命年。
- 增量成本-效用比为46083加元/质量调整生命年(2016年加元,年贴现率1.5%)。
- 在50000和100000加元/质量调整生命年支付意愿阈值下,经导管策略仅在52.7%和55.4%的模拟中为首选。
核心结论
- 基于当前证据,经导管主动脉瓣植入对于中危重度主动脉瓣狭窄患者可能具有成本-效用。
- 基础病例增量成本-效用比仍存在中至高度不确定性。
研究设计与样本
- 构建全概率马尔可夫模型,周期为30天,从加拿大第三方支付方角度分析。
- 比较经导管主动脉瓣植入与外科主动脉瓣置换,时间跨度为终生,年贴现率1.5%。
- 疗效输入数据来自The Placement of Aortic Transcatheter Valve 2临床试验。
- 成本数据来自加拿大健康信息研究所和安大略省收益表,调整为2016年加元。
- 计算增量成本-效用比。
主要发现
- 基础病例分析中,经导管主动脉瓣植入终生总成本较外科主动脉瓣置换高10548加元。
- 经导管主动脉瓣植入较外科主动脉瓣置换增加0.23个质量调整生命年。
- 增量成本-效用比为46083加元/质量调整生命年。
- 确定性单因素分析显示增量成本-效用比对并发症发生率和经导管主动脉瓣植入假体成本敏感。
- 在50000加元/质量调整生命年支付意愿阈值下,经导管主动脉瓣植入在52.7%的模拟中为首选;在100000加元/质量调整生命年阈值下,该比例为55.4%。
局限性
- 存在中至高度参数不确定性。
- 在50000和100000加元/质量调整生命年支付意愿阈值下,经导管主动脉瓣植入仅在52.7%和55.4%的模拟中为首选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although transcatheter aortic valve implantation has been shown to be noninferior to surgical aortic valve replacement in patients with severe aortic stenosis at intermediate surgical risk, the cost-effectiveness of this strategy in this population is unknown. Our objective was to conduct a cost-utility analysis comparing transcatheter aortic valve implantation with surgical aortic valve replacement in the population with intermediate risk severe aortic stenosis. METHODS: A fully probabilistic Markov model with 30-day cycles was constructed from the Canadian third-party payer's perspective to estimate the difference in cost and effectiveness (measured as quality-adjusted life years) of transcatheter aortic valve implantation versus surgical aortic valve replacement for intermediate-risk patients over a lifetime time horizon, discounted at 1.5% per annum. Clinical trial data from The Placement of Aortic Transcatheter Valve 2 informed the efficacy inputs. Costs (adjusted to 2016 Canadian dollars) were obtained from the Canadian Institute of Health Information and the Ontario Schedule of Benefits. Incremental cost-effectiveness ratios were calculated. RESULTS: In the base-case analysis, total lifetime costs for transcatheter aortic valve implantation were $10,548 higher than surgical aortic valve replacement but added 0.23 quality-adjusted life years, for an incremental cost-effectiveness ratio of $46,083/quality-adjusted life-years gained. Deterministic 1-way analyses showed that the incremental cost-effectiveness ratio was sensitive to rates of complications and cost of the transcatheter aortic valve implantation prosthesis. There was moderate-to-high parameter uncertainty; transcatheter aortic valve implantation was the preferred option in only 52.7% and 55.4% of the simulations at a $50,000 and $100,000 per quality-adjusted life years willingness-to-pay thresholds, respectively. CONCLUSIONS: On the basis of current evidence, transcatheter aortic valve implantation may be cost-effective for the treatment of severe aortic stenosis in patients with intermediate surgical risk. There remains moderate-to-high uncertainty surrounding the base-case incremental cost-effectiveness ratio.
引用
- Tam DY, Hughes A, Fremes SE, et al. A cost-utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical risk. J Thorac Cardiovasc Surg. 2018. PMID: 29454487. doi:10.1016/j.jtcvs.2017.11.112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。